[go: up one dir, main page]

PT2264009T - Composto do ácido piridilaminoacético - Google Patents

Composto do ácido piridilaminoacético

Info

Publication number
PT2264009T
PT2264009T PT09721163T PT09721163T PT2264009T PT 2264009 T PT2264009 T PT 2264009T PT 09721163 T PT09721163 T PT 09721163T PT 09721163 T PT09721163 T PT 09721163T PT 2264009 T PT2264009 T PT 2264009T
Authority
PT
Portugal
Prior art keywords
acid compound
pyridylaminoacetic acid
pyridylaminoacetic
compound
acid
Prior art date
Application number
PT09721163T
Other languages
English (en)
Inventor
Ryo C/O Ube Industries Ltd Iwamura
Masayuki C/O Ube Industries Ltd Tanaka
Tetsushi C/O Ube Industries Ltd Katsube
Manabu C/O Ube Industries Ltd Shigetomi
Eiji C/O Ube Industries Ltd Okanari
Yasunori C/O Ube Industries Ltd Tokunaga
Hiroshi C/O Ube Industries Ltd Fujiwara
Original Assignee
Ube Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41065261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2264009(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ube Industries filed Critical Ube Industries
Publication of PT2264009T publication Critical patent/PT2264009T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
PT09721163T 2008-03-12 2009-03-12 Composto do ácido piridilaminoacético PT2264009T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008062926 2008-03-12

Publications (1)

Publication Number Publication Date
PT2264009T true PT2264009T (pt) 2019-04-29

Family

ID=41065261

Family Applications (1)

Application Number Title Priority Date Filing Date
PT09721163T PT2264009T (pt) 2008-03-12 2009-03-12 Composto do ácido piridilaminoacético

Country Status (18)

Country Link
US (2) US8648097B2 (pt)
EP (1) EP2264009B1 (pt)
JP (3) JP5136640B2 (pt)
KR (1) KR101609001B1 (pt)
CN (2) CN103965099A (pt)
AU (1) AU2009224329B2 (pt)
CA (1) CA2718393C (pt)
CY (1) CY1121543T1 (pt)
DK (1) DK2264009T3 (pt)
ES (1) ES2718813T3 (pt)
HR (1) HRP20190509T1 (pt)
HU (1) HUE042839T2 (pt)
LT (1) LT2264009T (pt)
PL (1) PL2264009T3 (pt)
PT (1) PT2264009T (pt)
SI (1) SI2264009T1 (pt)
TR (1) TR201904655T4 (pt)
WO (1) WO2009113600A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2264009T1 (sl) 2008-03-12 2019-05-31 Ube Industries, Ltd. Spojina piridilaminoocetne kisline
SI2415763T1 (sl) 2009-03-30 2016-05-31 Ube Industries, Ltd. Farmacevtski sestavek za zdravljenje ali preprečevanje glavkoma
CN102548985A (zh) * 2009-09-11 2012-07-04 宇部兴产株式会社 取代羰基化合物
WO2011030873A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 ベンジル化合物
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
CA2773997A1 (en) * 2009-09-11 2011-03-17 Ube Industries, Ltd. Aniline compound
WO2011030865A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 置換ベンジル化合物
WO2011030871A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 N-置換ヘテロアリール化合物
WO2011030872A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 スルホンアミド化合物
CN102666490A (zh) * 2009-12-25 2012-09-12 宇部兴产株式会社 氨基吡啶化合物
KR101409137B1 (ko) 2010-03-12 2014-06-17 닛뽕소다 가부시키가이샤 피리딘 고리 함유 화합물, 및 할로겐화피콜린 유도체 및 테트라졸릴옥심 유도체의 제조 방법
EP2547204A2 (de) * 2010-03-18 2013-01-23 Bayer Intellectual Property GmbH Aryl- und hetarylsulfonamide als wirkstoffe gegen abiotischen pflanzenstress
EP2471363A1 (de) 2010-12-30 2012-07-04 Bayer CropScience AG Verwendung von Aryl-, Heteroaryl- und Benzylsulfonamidocarbonsäuren, -carbonsäureestern, -carbonsäureamiden und -carbonitrilen oder deren Salze zur Steigerung der Stresstoleranz in Pflanzen
JPWO2014157672A1 (ja) * 2013-03-28 2017-02-16 宇部興産株式会社 置換ビアリール化合物
KR20160047576A (ko) * 2013-09-02 2016-05-02 우베 고산 가부시키가이샤 폐질환의 치료 및/또는 예방을 위한 의약 조성물
WO2015105135A1 (ja) 2014-01-10 2015-07-16 参天製薬株式会社 ピリジルアミノ酢酸化合物含有医薬組成物
WO2015105144A1 (ja) * 2014-01-10 2015-07-16 参天製薬株式会社 ピリジルアミノ酢酸化合物を含む医薬製剤
GEAP201814216A (en) 2014-01-10 2018-07-25 Santen Pharmaceutical Co Ltd Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
CA2951790C (en) * 2014-06-10 2022-05-31 Ube Industries, Ltd. Method for producing heteroaromatic sulfonamide compound
US10774072B2 (en) 2014-06-10 2020-09-15 Ube Industries, Ltd. Crystal of N-substituted sulfonamide compound
US10428046B2 (en) 2014-06-10 2019-10-01 Ube Industries, Ltd. N-substituted sulfonamide compound and method for producing same
JP2017206445A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 呼吸器疾患の治療及び/又は予防のための医薬組成物
JP2017206443A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 置換ビアリール化合物及び他の医薬の組み合わせ
WO2017006985A1 (ja) 2015-07-09 2017-01-12 参天製薬株式会社 ピリジルアミノ酢酸化合物を含有する予防及び/又は治療剤
WO2018108627A1 (de) 2016-12-12 2018-06-21 Bayer Cropscience Aktiengesellschaft Verwendung substituierter indolinylmethylsulfonamide oder deren salze zur steigerung der stresstoleranz in pflanzen
WO2019025153A1 (de) 2017-07-31 2019-02-07 Bayer Cropscience Aktiengesellschaft Verwendung von substituierten n-sulfonyl-n'-aryldiaminoalkanen und n-sulfonyl-n'-heteroaryldiaminoalkanen oder deren salzen zur steigerung der stresstoleranz in pflanzen
US10940144B2 (en) 2017-09-29 2021-03-09 Santen Pharmaceutical Co., Ltd. Drug containing pyridylaminoacetic acid compound
US20210106569A1 (en) 2017-12-21 2021-04-15 Santen Pharmaceutical Co., Ltd. Omidenepag combination
CN111526876A (zh) 2017-12-28 2020-08-11 参天制药株式会社 含有吡啶基氨基乙酸化合物的药物制剂
CN118084895B (zh) * 2024-02-28 2025-09-05 中国药科大学 一种一氧化氮供体型Omidenepag衍生物及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019300A1 (en) 1990-06-08 1991-12-12 Sps Technologies, Incorporated Improved magnetic materials and process for producing the same
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
AP2000001889A0 (en) 1998-01-27 2000-09-30 Aventis Pharm Prod Inc Substituted ozoazaheterocyclyl factor Xa inhibitors.
AU2001290250A1 (en) 2000-09-21 2002-04-02 Ono Pharmaceutical Co. Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
WO2003016254A1 (en) * 2001-08-09 2003-02-27 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
AU2001297521B2 (en) 2001-10-26 2007-10-04 Allergan, Inc. Co-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
OA12760A (en) 2002-01-31 2006-07-04 Pfizer Prod Inc Metabolites of (3-ÄÄ4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-aminoÜ-methylÜ-phenoxy)-acetic acid.
CA2477715A1 (en) * 2002-03-05 2003-09-12 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient
KR20050105511A (ko) 2003-03-04 2005-11-04 화이자 프로덕츠 인크. 의학적 치료에서 ep2 선택적 수용체 효능제의 용도
GB0329620D0 (en) 2003-12-22 2004-01-28 Pharmagene Lab Ltd EP2 receptor agonists
JP2007186424A (ja) 2004-11-26 2007-07-26 Ono Pharmaceut Co Ltd 気管支拡張剤
WO2005072743A1 (ja) 2004-01-30 2005-08-11 Ono Pharmaceutical Co., Ltd. 気管支拡張剤
JP4734119B2 (ja) 2004-02-12 2011-07-27 田辺三菱製薬株式会社 インダゾール化合物及びその医薬用途
EP1593671A1 (en) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
JP2008503490A (ja) 2004-06-17 2008-02-07 センジェント・セラピューティクス・インコーポレイテッド チロシンホスファターゼの三置換窒素調節物質
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
CA2593439C (en) 2005-01-14 2014-02-25 F. Hoffmann-La Roche Ag Thiazole-4-carboxamide derivatives as mglur5 antagonists
WO2006106711A1 (ja) 2005-03-30 2006-10-12 Eisai R & D Management Co., Ltd. ピリジン誘導体を含有する抗真菌剤
EP1912957A4 (en) 2005-08-03 2009-05-13 Merck Frosst Canada Ltd EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS
US8080567B2 (en) * 2005-08-09 2011-12-20 Asterand Uk Limited EP2 receptor agonists
US7696235B2 (en) * 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
CA2659184C (en) * 2006-07-28 2012-02-21 Pfizer Products Inc. Ep2 agonists
UA94953C2 (en) * 2006-07-28 2011-06-25 Пфайзер Продактс Инк. Ep2 agonists
SI2264009T1 (sl) 2008-03-12 2019-05-31 Ube Industries, Ltd. Spojina piridilaminoocetne kisline
SI2415763T1 (sl) * 2009-03-30 2016-05-31 Ube Industries, Ltd. Farmacevtski sestavek za zdravljenje ali preprečevanje glavkoma

Also Published As

Publication number Publication date
CA2718393A1 (en) 2009-09-17
US20140113907A1 (en) 2014-04-24
HRP20190509T1 (hr) 2019-05-03
CN101970410B (zh) 2014-06-25
AU2009224329B2 (en) 2013-11-07
JP5136640B2 (ja) 2013-02-06
JP5545344B2 (ja) 2014-07-09
CN101970410A (zh) 2011-02-09
US20110054172A1 (en) 2011-03-03
CN103965099A (zh) 2014-08-06
EP2264009B1 (en) 2019-03-06
AU2009224329A1 (en) 2009-09-17
EP2264009A4 (en) 2012-08-01
KR101609001B1 (ko) 2016-04-04
TR201904655T4 (tr) 2019-06-21
WO2009113600A1 (ja) 2009-09-17
LT2264009T (lt) 2019-04-25
JP2014177476A (ja) 2014-09-25
JPWO2009113600A1 (ja) 2011-07-21
CY1121543T1 (el) 2020-05-29
ES2718813T3 (es) 2019-07-04
CA2718393C (en) 2015-06-16
JP2013063994A (ja) 2013-04-11
PL2264009T3 (pl) 2019-07-31
DK2264009T3 (en) 2019-04-15
EP2264009A1 (en) 2010-12-22
US8648097B2 (en) 2014-02-11
KR20100123903A (ko) 2010-11-25
SI2264009T1 (sl) 2019-05-31
HUE042839T2 (hu) 2019-07-29

Similar Documents

Publication Publication Date Title
LT2264009T (lt) Piridilaminoacto rūgšties junginys
ZA201008096B (en) Carboxylic acid compound
GB0818033D0 (en) Novel compound
SI2192109T1 (sl) Biciklični aminokislinski derivati
GB0800035D0 (en) Compounds
GB0804989D0 (en) Compound
ZA201000869B (en) Phenylacetic acid compound
GB0803494D0 (en) Compound
IL207035A0 (en) Benzylpiperizine compound
IL206524A0 (en) 4-dimethylminobutyric acid derivatives
GB0800367D0 (en) Compounds
GB0823316D0 (en) Compound
GB0801220D0 (en) Compounds
GB0801265D0 (en) Compounds
GB0820919D0 (en) Compound
GB0820915D0 (en) Compound
GB0807158D0 (en) Compound
GB0815806D0 (en) Compound
GB0802193D0 (en) Compound
GB0820249D0 (en) Compound
GB0805430D0 (en) Compound
GB0822635D0 (en) Compound
GB0820918D0 (en) Compound
GB0802227D0 (en) Compound
GB0806844D0 (en) Compound